-
Mashup Score: 52NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer - 2 day(s) ago
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS We established a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non–EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer - 3 day(s) ago
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS We established a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non–EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer - 3 day(s) ago
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS We established a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non–EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2The Limits of Clinician Vigilance as an AI Safety Bulwark - 5 day(s) ago
This Viewpoint examines the potential problems of clinician reliance on the use of artificial intelligence (AI) in health care and offers suggestions on how AI could be designed to promote clinician vigilance.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
Achetez et téléchargez ebook Sin velo: Cómo el progresismo legitima al islam radical (Spanish Edition): Boutique Kindle – Société : Amazon.fr
Source: www.amazon.frCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Dall’11 Settembre 2001 il mondo occidentale ha cominciato a preoccuparsi per l’islam e per il suo ruolo nel terrorismo. Tuttavia il dibattito pubblico sulla fede si è polarizzato: da un lato si elogia “la religione di pace”, dall’altro si afferma che tutti i musulmani sono terroristi. Yasmine Moh…
Source: www.amazon.itCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Depuis le 11 septembre 2001, le monde occidental est particulièrement préoccupé par le terrorisme islamique, mais le débat public est polarisé. D’un côté, on prétend que l’islam est « une religion de paix » ; de l’autre, que les musulmans sont des terroristes. La militante et activiste Yasmine Mo…
Source: www.amazon.frCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Entschleiert: Mein Ausbruch aus meiner radikal-islamischen Familie, mein Weg in die Freiheit - 5 day(s) ago
Entschleiert: Mein Ausbruch aus meiner radikal-islamischen Familie, mein Weg in die Freiheit
Source: www.amazon.frCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5العربية - 5 day(s) ago
جلس دعاة تفكك الدين أو ما يعرفون بالفرسان الأربعة وهم ريشارد دوكينز وكرستفر ه يتشنز وسام هارس ودانيال دانت في فجر ظهور الحركات اللإلحادية حول كوكتال من المشروبات فتبع ذلك حوار صارم، رائع، وآسر شاهده الملايين من المتابعين منذ أن نشر على موقع اليوتوب. إنها تساؤلات فكرية في أبهى تجلياتها حيث كانت ممتعة مضحكة وصادقة مباغتة واستقصائية في نفس الوقت تذكرنا بمدى تنوع واختلاف مقاربات الإلحاد المعاصرة. يقدم دوكينز في كتابه إجابة أنيقة تبين أن عملية الانتخاب الداروينية المعقدة عملية تلقائية وغير واعية. إذا أمكننا
Source: translationsproject.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer - 6 day(s) ago
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC. MATERIALS AND METHODS We established a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non–EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
RT @Markuseckstein3: We are happy to share our new study published today @JCO_ASCO (👉 https://t.co/NJtUVRVJ0Q) on the role of NECTIN4 ampli…